|
Company
|
Deal
description
|
Partner
|
Financial
terms
|
Date
|
|
Aileron
Therapeutics Inc.
|
Discover,
develop, and commercialize stapled peptide therapeutics
|
Roche (SIX:ROG; OTCQX:RHHBY)
|
$25M
technology access fees and R&D support; $1.1B in milestones, plus
royalties
|
Aug-2010
|
|
Ensemble
Therapeutics Corp.
|
Use
DNA-Programmed Chemistry technology to screen and identify macrocyclic
Ensemblins against partners' undisclosed targets
|
Bristol-Myers
Squibb Co. (NYSE:BMY)
|
$5M
up front; $7.5M in research support; $30M in milestones per compound, plus
royalties
|
Apr-2009
|
|
Genentech
Inc./Roche (SIX:ROG;
OTCQX:RHHBY)
|
Undisclosed
upfront payments, milestones and royalties
|
May-2012
|
|
Pfizer
Inc. (NYSE:PFE)
|
Undisclosed
upfront payments, research funding, milestones and royalties
|
Jan-2010
|
|
Lanthio
Pharma B.V.
|
Exclusive,
worldwide rights to lanthionine-Ang(1-7) peptide targeting MAS receptor in
preclinical development for acute lung injury
|
Tarix
Pharmaceuticals Ltd.
|
Undisclosed
milestones and royalties
|
Feb-2012
|
|
Oncodesign
S.A.
|
Discover
and develop compounds using Nanocyclix medicinal chemistry technology;
Nanocyclix is based on macrocyclic chemistry technology from Johnson &
Johnson (NYSE:JNJ)
|
Ipsen
Group (Euronext:IPN)
|
Undisclosed
technology access fee and funding; €115M ($148.8M) in
opt-in fees and milestones
|
Jan-2012
|
|
Sanofi
(Euronext:SAN; NYSE:SNY)
|
€130M ($166.2M)
technology access fee and milestones, plus low single-digit royalties
|
Sep-2012
|
|
Polyphor
Ltd.
|
Use
Macrofinder and/or Protein Epitope Mimetics (PEM) finder technologies to
identify macrocyclic molecules
|
Allergan
Inc. (NYSE:AGN)
|
$7M
up front; $61M in milestones, plus royalties.
|
Oct-2008
|
|
Axxam
S.p.A. (ion channel targets)
|
ND
|
Apr-2010
|
|
Axxam
S.p.A. (glucagon-like peptide-1
receptor (GLP-1R) modulators)
|
Funding
from Eurostars grant
|
Jul-2011
|
|
Boehringer
Ingelheim GmbH
|
Undisclosed
upfront payments, research funding, milestones and royalties
|
Jun-2012
|
|
Novartis
AG (NYSE:NVS; SIX:NOVN)
|
Undisclosed
upfront payments, research funding, milestones and royalties
|
May-2010
|
|
PeptiDream
Inc.
|
Use
cyclic peptide mRNA display technology to identify and develop hits against
partners' undisclosed targets
|
Amgen
Inc. (NASDAQ:AMGN)
|
ND
|
Oct-2010
|
|
Bristol-Myers
Squibb Co. (NYSE:BMY)
|
ND
|
Nov-2010
|
|
Daiichi
Sankyo Co. Ltd. (Tokyo:4568;
Osaka:4568)
|
ND
|
Jul-2012
|
|
MedImmune
LLC/AstraZeneca plc (LSE:AZN;
NYSE:AZN)
|
ND
|
Jul-2007
|
|
Mitsubishi
Tanabe Pharma Corp. (Tokyo:4508;
Osaka:4508)
|
ND
|
Dec-2010
|
|
Novartis
AG (NYSE:NVS; SIX:NOVN)
|
ND
|
Aug-2010
|
|
Pfizer
Inc. (NYSE:PFE)
|
ND
|
Dec-2010
|
|
Pepscan
Therapeutics B.V.
|
Develop
peptides using constrained peptide chemistry technology
|
Alvos
Therapeutics Inc. (now part of Arrowhead Research Corp. (NASDAQ:ARWR))
|
Undisclosed
research funding, milestones and royalties
|
Jan-2011
|
|
Bicycle
Therapeutics Ltd.
|
ND
|
Nov-2009
|
|
Johnson
& Johnson (NYSE:JNJ)
|
Undisclosed
research funding, milestones and royalties
|
Sep-2010
|
|
Phylogica
Ltd. (ASX:PYC; Xetra:PH7)
|
ND
|
May-2011
|
|
Zealand
Pharma A/S (CSE:ZEAL)
|
Fund
a portion of the work through a €860K ($1.2M) EUREKA
Eurostars grant; no other details disclosed
|
Mar-2011
|
|
Protagonist
Therapeutics Inc.
|
Discover
and develop disulfide rich peptides (DRPs) against partners' undisclosed
targets
|
Ironwood
Pharmaceuticals Inc. (NASDAQ:IRWD)
|
Undisclosed
upfront payments, milestones and royalties
|
Jan-2011
|
|
Zealand
Pharma A/S (CSE:ZEAL)
|
Undisclosed
upfront payments, milestones and royalties
|
Jun-2012
|
|
Tranzyme
Inc. (NASDAQ:TZYM)
|
Macrocyclic
Template Chemistry (MATCH) technology to discover, develop and commercialize
macrocyclic compounds
|
Bristol-Myers
Squibb Co. (NYSE:BMY)
|
$10M
up front; additional research funding; $80M in milestones per target program,
plus tiered royalties
|
Dec-2009
|